Search

Your search keyword '"Ballinger M"' showing total 151 results
Start Over Author "Ballinger M" Publication Year Range Last 10 years
151 results on '"Ballinger M"'

2. OA15.04 Comparison of Digital Vs Manual PD-L1 Tumour Cell Scoring on SP263-Stained Whole Imaging Slides from IMpower110

Author

Herbst, R.S., primary, Ruderman, D., additional, Conway, J., additional, Prizant, H., additional, Hennek, S., additional, Shamshoian, J., additional, Abel, J., additional, Montalto, M., additional, Beck, A., additional, Wapinski, I., additional, Molinero, L., additional, Amin, R., additional, Hoang, T., additional, Ballinger, M., additional, de Marinis, F., additional, Giaccone, G., additional, Jassem, J., additional, Giltnane, J., additional, Srivastava, M.K., additional, and Spigel, D.R., additional

Published
2023
Full Text
View/download PDF

3. MA11.08 IMpower010: Exploratory Analysis of Tumour Mutational Burden and Disease-Free Survival with Adjuvant Atezolizumab in NSCLC

Author

Felip, E., primary, Srivastava, M., additional, Reck, M., additional, Wakelee, H., additional, Altorki, N., additional, Vallieres, E., additional, Liersch, R., additional, Oizumi, S., additional, Tanaka, H., additional, Hamm, J.T., additional, Novello, S., additional, McCune, S., additional, Molinero, L., additional, McNally, V., additional, Morris, S., additional, Ballinger, M., additional, Li, H., additional, Zou, W., additional, Nabet, B.J., additional, Bennett, E., additional, Gitlitz, B.J., additional, and Zhou, C., additional

Published
2023
Full Text
View/download PDF

4. 1O IMpower010: ctDNA status in patients (pts) with resected NSCLC who received adjuvant chemotherapy (chemo) followed by atezolizumab (atezo) or best supportive care (BSC)

Author

Felip, E., primary, Srivastava, M., additional, Reck, M., additional, Wakelee, H., additional, Altorki, N.K., additional, Vallieres, E., additional, Liersch, R., additional, Harada, M., additional, Tanaka, H., additional, Hamm, J.T., additional, McCune, S., additional, Bennett, E., additional, Gitlitz, B.J., additional, McNally, V.A., additional, Novello, S., additional, Ballinger, M., additional, Zou, W., additional, Nabet, B., additional, Das Thakur, M., additional, and Zhou, C., additional

Published
2022
Full Text
View/download PDF

6. 2O IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC

Author

Zhou, C., primary, Das Thakur, M., additional, Srivastava, M.K., additional, Zou, W., additional, Xu, H., additional, Ballinger, M., additional, Felip, E., additional, Wakelee, H., additional, Altorki, N.K., additional, Reck, M., additional, Liersch, R., additional, Kryzhanivska, A., additional, Harada, M., additional, Tanaka, H., additional, Hamm, J., additional, McCune, S., additional, McNally, V., additional, Bennett, E., additional, Gitlitz, B., additional, and Novello, S., additional

Published
2021
Full Text
View/download PDF

8. 1264MO IMpower010: Exploratory analysis of disease-free survival (DFS) by TGFβ cancer-associated fibroblast (CAF) gene signature expression in patients (pts) with resected NSCLC treated with atezolizumab (atezo) or best supportive care (BSC)

Author

Altorki, N.K., Reck, M., Wakelee, H., Felip, E., Vallieres, E., Liersch, R., Oizumi, S., Tanaka, H., Novello, S., McCune, S., Li, H., Molinero, L., Müller, S., Bennett, E., Gitlitz, B.J., McNally, V.A., Ballinger, M., Nabet, B., Srivastava, M.K., and Zhou, C.

Published
2023
Full Text
View/download PDF

9. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel

Author

Gandara, D., Reck, M., Moro-Sibilot, D., Mazieres, J., Gadgeel, S., Morris, S., Cardona, A., Mendus, D., Ballinger, M., Rittmeyer, A., and Peters, S.

Subjects
immunotherapy, lung neoplasms
Abstract

Treatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to develop clinically relevant and applicable criteria for fast progression (FP), incorporating tumor growth kinetics and early death from disease progression to analyze data from the randomized phase III OAK study. The OAK study evaluated the efficacy and safety of atezolizumab versus docetaxel as second-line or third-line treatment for stage IIIb/IV non-small cell lung cancer. FP rates and associated baseline factors were analyzed. FP was defined as either a ≥50% increase in the sum of largest diameters (SLDs) within 6 weeks of treatment initiation or death due to cancer progression within 12 weeks (absent post-baseline scan). Forty-two of 421 patients (10%) receiving atezolizumab and 37 of 402 (9%) receiving docetaxel had FP. Twenty patients with FP (48%) receiving atezolizumab versus 12 (30%) receiving docetaxel had a ≥50% SLD increase within 6 weeks. FP was significantly associated with an ECOG (Eastern Cooperative Oncology Group) performance status of 1 (vs 0), ≥3 metastatic sites at baseline, and failure of preceding first-line treatment within 6 months, but not with epidermal growth factor receptor mutation, programmed cell death 1 ligand 1 or tumor mutational burden. Overall survival in patients with FP and a ≥50% SLD increase at week 6 was similar with atezolizumab and docetaxel (unstratified HR 0.89 (95% CI 0.41 to 1.92)). FP rates were similar with atezolizumab and docetaxel in the OAK study, suggesting that FP may not be unique to checkpoint inhibitors, although the underlying mechanisms may differ from those of chemotherapy. Applying the FP criteria to other phase III checkpoint inhibitor trials may further elucidate the risk factors for FP. NCT02008227.

Published
2021

10. P77.02 Efficacy of Tiragolumab + Atezolizumab in PD-L1 IHC and TIGIT Subgroups in the Phase II CITYSCAPE Study in First-Line NSCLC

Author

Patil, N., primary, Cho, B.C., additional, Johnson, M., additional, Caro, R.B., additional, Spira, A., additional, Chiu, C., additional, Molden, N., additional, Pham, T., additional, Yang, X., additional, Choi, Y., additional, Zhang, Z., additional, Hoang, T., additional, Ballinger, M., additional, Meng, R., additional, and Rodríguez-Abreu, D., additional

Published
2021
Full Text
View/download PDF

15. IMpower150: analysis of efficacy in patients (pts) with liver metastases (mets)

Author

Reck, M, additional, Jotte, R, additional, Cappuzzo, F, additional, Mok, T, additional, West, H, additional, Nishio, M, additional, Papadimitrakopoulou, VA, additional, Orlandi, F, additional, Stroyakovskii, D, additional, Thomas, C, additional, Nogami, N, additional, Barlesi, F, additional, Lee, A, additional, Shankar, G, additional, Yu, W, additional, Ballinger, M, additional, Bara, I, additional, Sandler, A, additional, and Socinski, M, additional

Published
2020
Full Text
View/download PDF

16. OA14.02 IMpower131: Final OS Results of Carboplatin + Nab-Paclitaxel ± Atezolizumab in Advanced Squamous NSCLC

Author

Jotte, R., primary, Cappuzzo, F., additional, Vynnychenko, I., additional, Stroyakovskiy, D., additional, Abreu, D. Rodriguez, additional, Hussein, M., additional, Soo, R., additional, Conter, H., additional, Kozuki, T., additional, Huang, K., additional, Graupner, V., additional, Sun, S., additional, Hoang, T., additional, Jessop, H., additional, Mccleland, M., additional, Ballinger, M., additional, Sandler, A., additional, and Socinski, M., additional

Published
2019
Full Text
View/download PDF

18. Pacific Northwest National Laboratory Annual Site Environmental Report for Calendar Year 2014

Author

Duncan, J. P., primary, Sackschewsky, M. R., additional, Tilden, H. T., additional, Su-Coker, J., additional, Mendez, J. L., additional, Ballinger, M. Y., additional, Fritz, B. G., additional, Stoetzel, G. A., additional, Barnett, J. M., additional, Lowry, K. L., additional, Moon, T. W., additional, Becker, J. M., additional, and Chamness, M. A., additional

Published
2015
Full Text
View/download PDF

19. Patient perspectives on molecular tumor profiling: 'why wouldn't you?'

Author

Best, MC, Bartley, N, Jacobs, C, Juraskova, I, Goldstein, D, Newson, AJ, Savard, J, Meiser, B, Ballinger, M, Napier, C, Thomas, D, Biesecker, B, Butow, P, Tucker, K, Schlub, T, Vines, R, Vines, K, Kirk, J, and Young, MA

Subjects
Adult, Male, Health Knowledge, Attitudes, Practice, Patients, Middle Aged, Survival Analysis, Cohort Studies, Patient Education as Topic, Neoplasms, Humans, Female, Oncology & Carcinogenesis, Patient Participation, Pathology, Molecular, Neoplasm Staging, Aged
Abstract

© 2019 The Author(s). Aim: This study explored the attitudes of patients with advanced cancer towards MTP and return of results, prior to undergoing genomic testing within a research program. Methods: Participants were recruited as part of the longitudinal PiGeOn (Psychosocial Issues in Genomics in Oncology) study involving patients with advanced/metastatic solid cancer who had exhausted therapeutic options and who were offered MTP in order to identify cognate therapies. Twenty patients, selected by purposive sampling, were interviewed around the time they gave consent to MTP. Interviews were audio recorded, transcribed and analysed using thematic analysis. Themes identified in the transcripts were cross-validated via qualitative responses to the PiGeOn study survey (n = 569; 63%). Results: All interviewed participants gave consent to MTP without reservation. Three themes were identified and further supported via the survey responses: (1) Obvious agreement to participate, primarily because of desire for new treatments and altruism. (2) The black box - while participant knowledge of genomics was generally poor, faith in their oncologists and the scientific process encouraged them to proceed with testing; and (3) Survival is the priority - receiving treatment to prolong life was the priority for all participants, and other issues such as identification of a germline variant were generally seen as ancillary. Conclusion: Having advanced cancer seemed to abrogate any potential concerns about MTP. Participants valued the research for varied reasons, but this was secondary to their priority to survive. While no negative attitudes toward MTP emerged, limitations in understanding of genomics were evident.

Published
2019

20. Late-differentiated effector neoantigen-specific CD8+ T cells are enriched in non-small cell lung carcinoma patients responding to atezolizumab treatment

Author

Fehlings, M., primary, Nardin, A., additional, Jhunjhunwala, S., additional, Kowanetz, M., additional, O'Gorman, B., additional, Hegde, P., additional, Li, J., additional, Sumatoh, H., additional, Lee, B., additional, Kim, L., additional, Flynn, S., additional, Ballinger, M., additional, Newell, E., additional, and Yadav, M., additional

Published
2019
Full Text
View/download PDF

21. Long-term survival in patients with advanced non–small-cell lung cancer treated with atezolizumab versus docetaxel: Results from the randomised phase III OAK study

Author

von Pawel, J., primary, Bordoni, R., additional, Satouchi, M., additional, Fehrenbacher, L., additional, Cobo, M., additional, Han, J.Y., additional, Hida, T., additional, Moro-Sibilot, D., additional, Conkling, P., additional, Gandara, D.R., additional, Rittmeyer, A., additional, Gandhi, M., additional, Yu, W., additional, Matheny, C., additional, Patel, H., additional, Sandler, A., additional, Ballinger, M., additional, Kowanetz, M., additional, and Park, K., additional

Published
2019
Full Text
View/download PDF

26. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the Ph III study OAK

Author

Reinmuth, N, additional, Syrigos, K, additional, Mazieres, J, additional, Cortinovis, D, additional, Dziadziuszko, R, additional, Gandara, D, additional, Conkling, P, additional, Goldschmidt, J, additional, Thomas, CA, additional, Bordoni, R, additional, Kosty, M, additional, Braiteh, F, additional, Hu, S, additional, Ballinger, M, additional, Patel, H, additional, Gandhi, M, additional, and Fehrenbacher, L, additional

Published
2018
Full Text
View/download PDF

27. Blood-Based Biomarkers for Cancer Immunotherapy: Tumor Mutational Burden in Blood (bTMB) is Associated with Improved Atezolizumab (atezo) Efficacy in 2L+ NSCLC (POPLAR and OAK)

Author

Rittmeyer, A, additional, Gandara, D, additional, Kowanetz, M, additional, Mok, T, additional, Fehrenbacher, L, additional, Fabrizio, D, additional, Otto, G, additional, Malboeuf, C, additional, Lieber, D, additional, Paul, SM, additional, Amler, L, additional, Riehl, T, additional, Schleifman, E, additional, Cummings, C, additional, Hegde, PS, additional, Zou, W, additional, Sandler, A, additional, Ballinger, M, additional, and Shames, DS, additional

Published
2018
Full Text
View/download PDF

28. Clinical Efficacy of atezolizumab (atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Author

Rittmeyer, A, additional, Gadgeel, S, additional, Kowanetz, M, additional, Zou, W, additional, Hirsch, FR, additional, Kerr, KM, additional, Gandara, D, additional, Barlesi, F, additional, Park, K, additional, McCleland, M, additional, Koeppen, H, additional, Ballinger, M, additional, Sandler, A, additional, and Hegde, PS, additional

Published
2018
Full Text
View/download PDF

29. MA 05.09 Pre-Existing Immunity Measured by Teff Gene Expression in Tumor Tissue is Associated with Atezolizumad Efficacy in NSCLC

Author

Kowanetz, M., primary, Zou, W., additional, Mccleland, M., additional, Gandara, D.R., additional, Gadgeel, S., additional, Rittmeyer, A., additional, Barlesi, F., additional, Park, K., additional, Shames, D., additional, Koeppen, H., additional, Ballinger, M., additional, Sandler, A., additional, and Hegde, P., additional

Published
2017
Full Text
View/download PDF

30. OA 17.07 Long-Term Survival in Atezolizumab-Treated Patients with 2L+ NSCLC from Ph III Randomized OAK Study

Author

Satouchi, M., primary, Fehrenbacher, L., additional, Dols, M. Cobo, additional, Han, J., additional, Von Pawel, J., additional, Bordoni, R., additional, Hida, T., additional, Park, K., additional, Moro-Sibilot, D., additional, Conkling, P., additional, Matheny, C., additional, Yu, W., additional, He, P., additional, Kowanetz, M., additional, Gandhi, M., additional, Ballinger, M., additional, Sandler, A., additional, and Gandara, D.R., additional

Published
2017
Full Text
View/download PDF

32. MA 10.03 3-Year Survival and Duration of Response in Randomized Phase II Study of Atezolizumab vs Docetaxel in 2L/3L NSCLC (POPLAR)

Author

Park, K., primary, Lewanski, C., additional, Gadgeel, S., additional, Fehrenbacher, L., additional, Mazieres, J., additional, Rittmeyer, A., additional, Han, J., additional, Artal-Cortes, A., additional, Braiteh, F., additional, Gandhi, M., additional, Yu, W., additional, Matheny, C., additional, He, P., additional, Sandler, A., additional, Ballinger, M., additional, and Vansteenkiste, J., additional

Published
2017
Full Text
View/download PDF

33. Le gisement paléolithique multistratifié d'Ormesson (Seine-et-Marne) : Palethnologie ou pâle ethnologie ?

Author

Bodu, P., Ballinger, M., Dumarçay, G., Goutas, N., Julien, M.A., Lacarriere, J., Legrand-Pineau, A., Lejay, M., Leroyer, M., Lucas, C., MOINE, O., NATON, H.G., Peschaux, C., Salomon, H., STOETZEL, E., Suire, J., THERY-PARISOT, I., TOUZE, O., Histoire naturelle de l'Homme préhistorique (HNHP), and Muséum national d'Histoire naturelle (MNHN)-Université de Perpignan Via Domitia (UPVD)-Centre National de la Recherche Scientifique (CNRS)

Subjects
[SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2016

34. The bison valley: Ormesson (Seine-et-Marne, France), a key open-air site for the study of Palaeolithic groups from the Middle Palaeolithic to the Badegoulian

Author

Touzé, O., Bodu, P., Ballinger, M., Dumarçay, G., Goutas, N., A Julien, M., Lacarrière, J., Lejay, M., Leroyer, M., Lucas, C., Moine, O., Henri-Georges Naton, Peschaux, C., Legrand-Pineau, A., Salomon, H., Stoetzel, E., Suire, J., Isabelle Théry-Parisot, Centre de Recherche Pierre Fabre, Laboratoire de géographie physique : Environnements Quaternaires et Actuels (LGP), Centre National de la Recherche Scientifique (CNRS)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Université Panthéon-Sorbonne (UP1), Histoire naturelle de l'Homme préhistorique (HNHP), Centre National de la Recherche Scientifique (CNRS)-Muséum national d'Histoire naturelle (MNHN)-Université de Perpignan Via Domitia (UPVD), Culture et Environnements, Préhistoire, Antiquité, Moyen-Age (CEPAM), Université Nice Sophia Antipolis (... - 2019) (UNS), Université Côte d'Azur (UCA)-Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS), F.R.S.-FNRS, Archéologies et Sciences de l'Antiquité (ArScAn), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris Nanterre (UPN)-Ministère de la Culture et de la Communication (MCC)-Centre National de la Recherche Scientifique (CNRS), University of Southampton (University of Southampton), Travaux et recherches archéologiques sur les cultures, les espaces et les sociétés (TRACES), Ministère de la Culture et de la Communication (MCC)-École des hautes études en sciences sociales (EHESS)-Université Toulouse - Jean Jaurès (UT2J)-Centre National de la Recherche Scientifique (CNRS), British Museum, Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Centre National de la Recherche Scientifique (CNRS), GeoArchEon SARL, Maison de l'Archéologie et de l'Ethnologie René-Ginouvès (MAE), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris Nanterre (UPN)-Centre National de la Recherche Scientifique (CNRS), Université de Liège, De la Préhistoire à l'Actuel : Culture, Environnement et Anthropologie (PACEA), Université de Bordeaux (UB)-Centre National de la Recherche Scientifique (CNRS), Muséum national d'Histoire naturelle (MNHN)-Centre National de la Recherche Scientifique (CNRS)-Université de Perpignan Via Domitia (UPVD), Université Côte d'Azur (UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA), École des hautes études en sciences sociales (EHESS)-Université Toulouse - Jean Jaurès (UT2J)-Ministère de la Culture et de la Communication (MCC)-Centre National de la Recherche Scientifique (CNRS), Muséum national d'Histoire naturelle (MNHN)-Université de Perpignan Via Domitia (UPVD)-Centre National de la Recherche Scientifique (CNRS), Université Paris 1 Panthéon-Sorbonne (UP1)-Université Paris 8 Vincennes-Saint-Denis (UP8)-Université Paris Nanterre (UPN)-Ministère de la Culture et de la Communication (MCC)-Institut national de recherches archéologiques préventives (Inrap)-Centre National de la Recherche Scientifique (CNRS), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Centre National de la Recherche Scientifique (CNRS)-Université Côte d'Azur (UCA), University of Southampton, and CEPAM, Labo

Subjects
[SHS.ARCHEO] Humanities and Social Sciences/Archaeology and Prehistory, [SHS.ARCHEO]Humanities and Social Sciences/Archaeology and Prehistory, bison, groups, Middle, valley, Badegoulian, from, Seine-et-Marne, site, study, France, Ormesson, open-air, ComputingMilieux_MISCELLANEOUS, Palaeolithic
Abstract

International audience; In the Paris Basin, open-air Palaeolithic sites generally belong to the finalMagdalenian with examples such as Pincevent, Etiolles and Verberie. It is onthese sites that the palethnographic approach of A. Leroi-Gourhan and hisdisciples was elaborated. However, for a long time, periods prior to the end ofthe Upper Palaeolithic did not focus a lot of attention, certainly because of theabsence of well-preserved sites, but also because of a relative lack of intereston behalf of researchers who were working on this vast area. Thanks to a collectiveresearch project developed in the early 2000’s at the French NationalCenter for Scientific research (CNRS), entitled “The Early Upper Palaeolithic ofthe centre and the south of the Paris Basin”, new data were collected leading tothe development of an excavation program on the site of Ormesson (Seine-et-Marne) that began in 2009. After seven years of functioning, this program,initially focused on a Gravettian occupation dated 26500 uncal. BP and linkedto bison hunting, has permitted the identification of four others occupationsranging from the end of the Middle Palaeolithic to the Badegoulian, and alsoincluding the Châtelperronian and the Middle Solutrean periods. The excellentstate of preservation of these occupations leads us, besides the study of theenvironmental context (topography, plant environment, fauna, availability ofraw materials, etc.), to a better understanding of subsistence economies andsettlements functioning developed during 30000 years of human presence atthis site.

Published
2016

35. Climate-associated tundra thaw pond formation and range expansion of boreal zooplankton predators

Author

Taylor D., Ballinger M., Medeiros A., and Kotov A.

Abstract

© 2015 Nordic Society Oikos. Most of the freshwater component of the Earth's surface is composed of shallow tundra ponds. These high latitude ecosystems have been exposed to a variety of abiotic disturbances associated with recent environmental change. However, the biological significance of these changes remains poorly understood. Here, we characterize the abiotic disturbance to the shallow tundra ponds of northwest Alaska. We used historical aerial imagery to determine that up to 53% of the sampled ponds have formed during the recent warmer decades (since the 1970s). We discovered that two top predator species (phantom midges of the genus Chaoborus) of the freshwater zooplankton have recently undergone range expansion, forming widespread (a scale of hundreds of km) stable tundra populations. We assessed the population persistence of these boreal predators by longitudinal sampling over 14 yr. Recent thaw ponds had significantly dissimilar zooplankton communities to communities of ponds that formed before 1950. Both predator and herbivore species differed by age of pond. Younger pond ages and warmer surface temperatures were the significant predictors of the presence of temperate Chaoborus americanus in tundra ponds. Ponds containing tundra populations of C. americanus and C. cf. flavicans were associated with recent formation (83-90%). Recent ponds in river valleys appeared more important than recent ponds near roads as colonization corridors for C. americanus. Only 24% of the tundra keystone predator, Heterocope septentrionalis, populations were from recent ponds. Our results suggest that climate-associated disturbance can lead to a widespread stable range expansion of boreal species despite the propinquity of older ponds with top-down control exerted by an endemic keystone predator.

Published
2016

37. Association between immune-related adverse events (irAEs) and atezolizumab efficacy in advanced NSCLC: analyses from the phase III study OAK

Author

von Pawel, J., primary, Syrigos, K., additional, Mazieres, J., additional, Cortinovis, D., additional, Dziadziuszko, R., additional, Gandara, D.R., additional, Conkling, P., additional, Goldschmidt, J., additional, Thomas, C.A., additional, Bordoni, R., additional, Kosty, M., additional, Braiteh, F.S., additional, Hu, S., additional, Ballinger, M., additional, Patel, H., additional, Gandhi, M., additional, and Fehrenbacher, L., additional

Published
2017
Full Text
View/download PDF

38. Survival and safety of atezolizumab by best overall response (BOR) in the phase III NSCLC OAK study

Author

de Marinis, F., primary, Barlesi, F., additional, Rittmeyer, A., additional, von Pawel, J., additional, Han, J.-Y., additional, Kozloff, M., additional, Spira, A., additional, Fehrenbacher, L., additional, Gandara, D.R., additional, Yu, W., additional, He, P., additional, Yun, C., additional, Ballinger, M., additional, Gandhi, M., additional, and Gadgeel, S., additional

Published
2017
Full Text
View/download PDF

39. Blood-based biomarkers for cancer immunotherapy: Tumor mutational burden in blood (bTMB) is associated with improved atezolizumab (atezo) efficacy in 2L+ NSCLC (POPLAR and OAK)

Author

Gandara, D.R., primary, Kowanetz, M., additional, Mok, T.S.K., additional, Rittmeyer, A., additional, Fehrenbacher, L., additional, Fabrizio, D., additional, Otto, G., additional, Malboeuf, C., additional, Lieber, D., additional, Paul, S.M., additional, Amler, L., additional, Riehl, T., additional, Schleifman, E., additional, Cummings, C.A., additional, Hegde, P.S., additional, Zou, W., additional, Sandler, A., additional, Ballinger, M., additional, and Shames, D.S., additional

Published
2017
Full Text
View/download PDF

40. Clinical efficacy of atezolizumab (Atezo) in PD-L1 subgroups defined by SP142 and 22C3 IHC assays in 2L+ NSCLC: Results from the randomized OAK study

Author

Gadgeel, S., primary, Kowanetz, M., additional, Zou, W., additional, Hirsch, F.R., additional, Kerr, K.M., additional, Gandara, D.R., additional, Barlesi, F., additional, Park, K., additional, McCleland, M., additional, Koeppen, H., additional, Ballinger, M., additional, Sandler, A., additional, Hegde, P.S., additional, and Rittmeyer, A., additional

Published
2017
Full Text
View/download PDF

41. Immune-related adverse events (irAEs) in advanced NSCLC patients treated with atezolizumab: Safety population analyses from the Ph III study OAK

Author

Cortinovis, D., primary, von Pawel, J., additional, Syrigos, K., additional, Mazieres, J., additional, Dziadziuszko, R., additional, Fehrenbacher, L., additional, Conkling, P., additional, Goldschmidt, J., additional, Thomas, C.A., additional, Bordoni, R., additional, Kosty, M., additional, Braiteh, F.S., additional, He, P., additional, Ballinger, M., additional, Gandhi, M., additional, Patel, H., additional, and Gandara, D.R., additional

Published
2017
Full Text
View/download PDF

43. Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

Author

Artal-Cortes, A., primary, Mazieres, J., additional, Fehrenbacher, L., additional, Rittmeyer, A., additional, Spira, A.I., additional, Park, K., additional, Lewanski, C., additional, Liu, S., additional, Ballinger, M., additional, and Vansteenkiste, J., additional

Published
2017
Full Text
View/download PDF

44. Updated survival and biomarker analyses of a randomized phase II study of atezolizumab vs. docetaxel in 2L/3L NSCLC (POPLAR)

Author

Rittmeyer, A, additional, Smith, D, additional, Vansteenkiste, J, additional, Fehrenbacher, L, additional, Park, K, additional, Mazieres, J, additional, Artal-Cortes, A, additional, Lewanski, C, additional, Braiteh, F, additional, Yi, J, additional, He, P, additional, Zou, W, additional, Waterkamp, D, additional, Ballinger, M, additional, Chen, DS, additional, Sandler, A, additional, and Spira, AI, additional

Published
2017
Full Text
View/download PDF

45. Efficacy, safety and predictive biomarker results from OAK, a randomized phase III study comparing atezolizumab with docetaxel in patients with advanced NSCLC

Author

Schütte, W, additional, Barlesi, F, additional, Park, K, additional, Ciardiello, F, additional, Pawel, J, additional, Gadgeel, S, additional, Hida, T, additional, Kowalski, D, additional, Cobo Dols, M, additional, Cortinovis, D, additional, Leach, J, additional, Polikoff, J, additional, Gandara, DR, additional, Barrios, C, additional, Chen, DS, additional, He, P, additional, Ballinger, M, additional, Waterkamp, D, additional, Sandler, A, additional, and Rittmeyer, A, additional

Published
2017
Full Text
View/download PDF

46. 438O Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Author

Park, K., primary, Barlesi, F., additional, Ciardiello, F., additional, von Pawel, J., additional, Gadgeel, S., additional, Hida, T., additional, Kowalski, D., additional, Cobo Dols, M., additional, Cortinovis, D., additional, Leach, J., additional, Polikoff, J., additional, Gandara, D.R., additional, Barrios, C., additional, Chen, D.S., additional, He, P., additional, Kowanetz, M., additional, Ballinger, M., additional, Waterkamp, D., additional, Sandler, A., additional, and Rittmeyer, A., additional

Published
2016
Full Text
View/download PDF

47. Primary analysis from OAK, a randomized phase III study comparing atezolizumab with docetaxel in 2L/3L NSCLC

Author

Barlesi, F., primary, Park, K., additional, Ciardiello, F., additional, von Pawel, J., additional, Gadgeel, S., additional, Hida, T., additional, Kowalski, D., additional, Dols, M.C., additional, Cortinovis, D., additional, Leach, J., additional, Polikoff, J., additional, Gandara, D., additional, Barrios, C.H., additional, Chen, D.S., additional, He, P., additional, Kowanetz, M., additional, Ballinger, M., additional, Waterkamp, D., additional, Sandler, A., additional, and Rittmeyer, A., additional

Published
2016
Full Text
View/download PDF

48. Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma

Author

Hwu, P., primary, Hamid, O., additional, Gonzalez, R., additional, Infante, J.R., additional, Patel, M.R., additional, Hodi, F.S., additional, Lewis, K.D., additional, Wallin, J., additional, Mwawasi, G., additional, Cha, E., additional, Richie, N., additional, Ballinger, M., additional, and Sullivan, R., additional

Published
2016
Full Text
View/download PDF

49. Tumor mutation load assessed by FoundationOne (FM1) is associated with improved efficacy of atezolizumab (atezo) in patients with advanced NSCLC

Author

Kowanetz, M., primary, Zou, W., additional, Shames, D.S., additional, Cummings, C., additional, Rizvi, N., additional, Spira, A.I., additional, Frampton, G.M., additional, Leveque, V., additional, Flynn, S., additional, Mocci, S., additional, Shankar, G., additional, Funke, R., additional, Ballinger, M., additional, Waterkamp, D., additional, Sandler, A., additional, Hampton, G., additional, Amler, L., additional, Hegde, P.S., additional, and Hellmann, M., additional

Published
2016
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results